Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties

• Authors: Kamila Skwierawska , Krzysztof Woźniak , Anna Waszczuk-Gajda , Joanna Drozd-Sokołowska , Piotr Kacprzyk , Marita Rachid Chehab , Piotr Boguradzki , Wiesław Wiktor Jędrzejczak , Grzegorz Władysław Basak
• Languages of publication: EN

Abstracts

EN

Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.

Keywords

EN

CR-MAHA; breast cancer; cancer-related microangiopathic hemolytic anemia; thrombocytopenia; thrombotic microangiopathy

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2020
• Volume: 10
• Issue: 4
• Pages: 134-138

Contributors

author

Kamila Skwierawska

• Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw

author

Krzysztof Woźniak

• Department of Oncology, Medical University of Warsaw

author

Anna Waszczuk-Gajda

• 1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

author

Joanna Drozd-Sokołowska

• 1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

author

Piotr Kacprzyk

• Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw

author

Marita Rachid Chehab

• Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw

author

Piotr Boguradzki

• 1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

author

Wiesław Wiktor Jędrzejczak

• 1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

author

Grzegorz Władysław Basak

• 1. Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw. 2. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw

References

• 1. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012; 91(4): 195-205.
• 2. Takabatake D, Oishi K. Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature review. Springerplus. 2016; 5(1): 684. http://doi.org/10.1186/s40064-016-2312-4.
• 3. Regierer AC, Kuehnhardt D, Schulz C et al. Breast Cancer-Associated Thrombotic Microangiopathy. Breast Care. 2011; 6: 441-5.
• 4. Hausberg M, Felten H, Pfeffer S. Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer. Case Rep Oncol. 2019; 12: 1-6.
• 5. Lee EH, Otoukesh S, Abdi A et al. Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia. Case Rep Oncol. 2019; 12: 104-8.
• 6. Lara K, Bae E, Park H et al. A rare case of concurrent signet-ring carcinoma of breast and microangiopathic hemolytic anemia. J Surg Case Rep. 2016; (9): rjw132.
• 7. Morton JM, George JN. Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. J Oncol Pract. 2016; 12(6): 523-30.
• 8. Babu KG, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016; 10: 649.
• 9. Chalasani P, Segar JM, Marron M et al: Pathophysiology of tumour-induced microangiopathic haemolytic anaemia. BMJ Case Rep. 2016; 2016.
• 10. Werner TL, Agarwal N, Carney HM et al. Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol. 2007; 82(4): 295-8.
• 11. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012; 30: 2601-8.
• 12. Meng X, Song S, Jiang ZF et al. Receptor conversion in metastatic breast cancer: a prognosticator of survival. Oncotarget. 2016; 7(44): 71887-903.

• Document Type: article